BOSTON, Mass. — An experimental once-daily pill in the same drug class as Viagra slowed decline in early Alzheimer's disease by about a third over one year in a large Phase 3 trial, according to topline results presented Monday, Nov. 16, 2026.
The drug is AR1001, also known as mirodenafil, developed by AriBio.
It is a PDE5 inhibitor, the class that includes sildenafil.
Results from the POLARIS-AD trial were presented at the Clinical Trials on Alzheimer's Disease conference in Boston by Dr. Sharon Sha, chief of the Memory Disorders Division at Stanford University and the trial's global principal investigator.
1,535 Patients, 52 Weeks, and a 3.5-Month Delay
POLARIS-AD enrolled 1,535 people with early Alzheimer's disease at about 230 sites in 13 countries.
Participants received AR1001 30 mg or a placebo once daily for 52 weeks.
A total of 1,348 participants, about 88%, completed the treatment period.
The primary endpoint was change in the Clinical Dementia Rating–Sum of Boxes (CDR-SB), a measure of cognitive and functional impairment.
Get help from someone local. Text HELP to (805) 719-7630 and we'll set up a time to talk that works for you.
Reporting on the presentation put the slowing at 31% in one trial group, equivalent to a delay of about 3.5 months over the year.
AriBio has also reported biomarker reductions with AR1001 30 mg in plasma p-tau181, p-tau217 and GFAP compared with placebo.
Investigational Drug, Earlier Miss, and No Approval
AR1001 has not been approved by the U.S. Food and Drug Administration or any other regulatory authority, and its safety and efficacy have not been established.
Its earlier 210-patient Phase 2 trial missed its primary cognitive and global endpoints at 26 weeks in the overall population, though a prespecified subgroup of patients not taking other Alzheimer's medicines showed improvement.
That history is why the full Phase 3 data set, including safety results and which analysis populations met the endpoint, matters more than the headline percentage.
More than 95% of eligible participants who finished the main study chose to continue in an optional extension in which everyone receives AR1001. AriBio says it plans to discuss a New Drug Application with the FDA if efficacy and safety are confirmed.
Sources
AriBio, POLARIS-AD topline results announcement for CTAD 2026, Nov. 9, 2026. CTAD 2026 programme, session OC2, Nov. 16, 2026.
Transparency notes
Published: Nov 16, 2026. Last updated: Nov 16, 2026.
Spot an error or missing context? Email hi@kindjoe.com and we will review and correct if needed.
Sources
External source links were not provided in this article body. Our editors reference publicly available materials and update stories as new verified information arrives.
What's your take on this story?
Vote before the outcome is known and compare your call with the crowd.
No community take has been linked to this story yet.
